Wall Street expects a year-over-year increase in earnings on higher revenues when Thermo Fisher Scientific (TMO) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 29, might help the stock move higher if these key numbers are better ...

Core Insights - Engine Capital Management has significantly increased its investment in Avantor, acquiring 14.2 million shares valued at approximately $172 million, raising its total stake to $246.1 million as of September 30 [2][3][10] Company Overview - Avantor, Inc. is a global supplier of essential products and services for biopharma, healthcare, education, and advanced technology sectors, leveraging a broad portfolio and integrated supply chain to meet complex customer needs [6][9] - The company reported a market capitalization of $7.5 billion and a revenue of $6.6 billion for the trailing twelve months (TTM) [4] Financial Performance - In the latest quarter, Avantor's net sales decreased by 5% to $1.6 billion, and a non-cash goodwill impairment of $785 million resulted in a GAAP net loss of $712 million [11] - Despite the losses, the company generated an adjusted EBITDA of $268 million and free cash flow of $172 million, indicating ongoing cash generation capabilities [11] Investment Thesis - Avantor now constitutes 29.2% of Engine Capital Management's assets under management (AUM), suggesting a strong conviction in the company's long-term value despite recent operational challenges [3][12] - The current market conditions present a classic recovery opportunity for long-term investors, characterized by durable end-market exposure and a reset in valuation driven by market sentiment rather than solvency concerns [10][12]

Core Insights - Avantor, Inc. is a global provider of mission-critical products and services in the life sciences and advanced technologies sectors, competing with major players like Thermo Fisher Scientific and Merck KGaA [1] Stock Performance - Avantor's stock is currently priced at $11.82, reflecting a 6.97% increase, amidst significant fluctuations [2] - The stock has a 52-week high of $23.705 and a low of $10.825, indicating a volatile market environment [4] - The recent price change of $0.77 and fluctuations between a low of $10.825 and a high of $11.90 highlight ongoing volatility [5] Shareholder Actions - The Rosen Law Firm is reaching out to Avantor stockholders who have suffered losses exceeding $100,000, indicating potential legal actions available to affected shareholders [2][6] - Director SUMME GREGORY L purchased 100,000 shares at $11.25 each, increasing his total holdings to 300,000 shares, which may signal confidence in the company's future prospects [3][6] Market Capitalization and Trading Volume - Avantor's market capitalization is approximately $8.06 billion, with a trading volume of 18.93 million shares, reflecting the company's presence in a volatile market [4]

Core Insights - Avantor, Inc. is a global provider of mission-critical products and services in the life sciences and advanced technologies sectors, competing with major players like Thermo Fisher Scientific and Merck KGaA [1] Financial Performance - Avantor's third-quarter 2025 financial results were disappointing, with adjusted earnings per share (EPS) decreasing by 15.4% year-over-year to $0.22, missing the Zacks Consensus Estimate by 4.4% [3][6] - The company reported a GAAP loss per share of $1.04, compared to an EPS of $0.08 in the same quarter last year [3] - Revenues for the quarter totaled $1.62 billion, representing a 5.3% decline from the previous year and falling short of the Zacks Consensus Estimate by 1.6% [4][6] - Organic sales declined by 4.7%, with core segments also posting declines [4][6] Stock Performance and Guidance - Following the disappointing financial performance, Avantor's stock price plunged by 23.2% [5][6] - The company revised its full-year 2025 guidance, projecting EPS to be between $0.88 and $0.92, with organic sales expected to decrease by up to 3.5% [5] - JPMorgan Chase and Co. adjusted the price target for Avantor from $17.00 to $14.00 [5] Insider Activity - On October 30, 2025, SUMME GREGORY L, a director at Avantor, purchased 100,000 shares at $11.25 per share, increasing his total holdings to 300,000 shares [2]